



23.

The method according to claim 22 wherein said fungus is *Cryptococcus neoformans*.

- 3 24. The method according to claim 23 wherein said host is a mammal.
- 4 25. The method according to claim 24 in which said mammal is a human.
- 5 26. The method according to claim 24 in which said composition is administered to said human by parenteral means.
- 6 27. The method according to claim 24 in which said composition is administered topically to said human.
- 7 28. The method according to claim 25 in which said composition is administered intravenously to said human.
- 8 29. The method according to claim 25 in which said active ingredient is administered in a suppository inserted in said host.
- 9 30. The method according to claim 24 in which said composition is administered to said mammal by parenteral means.
- E 10 31. The method according to claim 24 in which said composition is administered topically to said mammal.
- 11 32. The method according to claim 24 in which said composition is administered intravenously to said mammal.
- 12 33. The method according to claim 24 in which said composition is administered in a suppository inserted in said mammal.
- 13 34. The method according to claim 24 wherein said mammal is infected systematically with *Cryptococcus neoformans*.
- 14 35. The method according to claim 24 wherein the epidermis of said mammal is infected with *Cryptococcus neoformans*.
- 15 36. The method according to claim 31 wherein said carrier is selected from the group consisting of a water-and-oil emulsion, petrolatum, mineral oil, a moisturizer, and a solubilizer.
- 16 37. The method according to claim 27 wherein said carrier is selected from the group consisting of a water-and-oil emulsion, petrolatum, mineral oil, a moisturizer, and a solubilizer.
- 17 38. The method of claim 31 in which said carrier contains a fragrance.
- 18 39. The method of claim 37 in which said carrier contains a fragrance.

31

E